Durvalumab with chemotherapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid cancer that cannot be removed with surgery
- Your cancer has grown after at least one prior standard treatment, or there is no proven standard treatment to extend life
- A doctor can take a tumor biopsy (you agree to get one)
- Your cancer has measurable tumors on scans (there is at least one trackable spot)
- You are at least 18 years old and well enough to do daily activities (ECOG 0–2)
- Your blood and organ tests are within required limits (counts, liver/kidney function), and you’re not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
This trial tests adding durvalumab (an immune therapy) to a radiation treatment plan for people with non-small cell lung cancer (NSCLC) who can’t safely have chemotherapy at the same time or surgery first. It aims to improve cancer control after radiation by helping the immune system recognize and fight the tumor.
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
This Phase 2 trial studies a new treatment plan that combines RMT with durvalumab and chemotherapy in people with untreated advanced lung adenocarcinoma. It aims to improve outcomes by helping the immune system and fighting cancer cells together.
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
Hear when a new Locally Advanced Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.